Cordlife 2Q 2013 revenue increased by 21% to 8.8m.
Profit incresed by 192.7% to 5.6m. Profit excluding disposaal gain of 2.7m will be 3.0m, gain of 54.5%.
Gross margin maintained at 70%.
1H profit = 6.8m & dividend of 1 cts. Cordlife future looks very promising & a future muti-baggers.
Â
CORDLIFE 2nd Quarter 2013
* Records fourth consecutive quarter of revenue growth, driven by 21% year-on-year rise in number of clint deliveries * Achieves 192.7% increase in net profit to $5.6 million * Excluding one-time disposal gain, net profit grew 54.5% to $3.0 million * Gross margin maintained at strong level of 70% * Strong balance sheet with net cash position * Share of results kicks in from recent acquisitioin of 10% stake in China's largest cord blood banking operator * To potentially benefit from Singapore goverment's recent measures to boost population growth
I believe Health-care business are resilence in nature. Below listed Health-care stocks for a general comparison: Cordlife - 68 cents
PE around 15
PB about 2
Revenue growth about 20%. Profit about 50%
Net profit margin = 34%
 IHH - $1.335
PE about 70
PB 0.6
Revenue growth - not consistence
Net profit margin = 11% Pacific Healthcare - 7.5 cents
PE - making lost
PB about 3.5
Growth - Negative Q & M 32.5 cents
PE more than 30
PB more than 6
Revenue growth about 20%. Profit about 10%
Net profit margin about 10% Raffles Mediccal $3.15
PE more than 30
PB more than 4
Revenue growth about 10%. Profit about 10%.
Net profit margin less than 20%
CORDLIFE clearly top the lists in term of growth, profit margin & best of all yield. Useing PE as a comparison it's the cheapest.
Â
Cordlife announced Strategic Alliance Agreements with CordLabs Asia Pte. Ltd.
This Strategic Alliance Agreements with Cordlabs Asia Pte Lte should be positive for the company business.
